-
A large number of pharmaceutical companies announced that the product will be included in the National Medical Insurance Catalog (2021)
Time of Update: 2021-12-31
At the same time, on December 3, a large number of pharmaceutical companies issued announcements stating that their products were included in the National Medical Insurance Catalog (2021) .
-
Shuanglu Pharmaceutical DT678 Tablets Obtained the Notification of Drug Clinical Trial Approval
Time of Update: 2021-12-31
On December 7, Shuanglu Pharmaceutical issued an announcement stating that the company had recently received the "Drug Clinical Trial Approval Notice" issued by the State Drug Administration for DT678 tablets .
DT678 tablet is the world's first innovative drug in the field of anti-platelet aggregation drugs.
-
Russia approves clinical trials of innovative breast cancer drugs
Time of Update: 2021-12-31
On December 7, according to a report by the Financial Association, the Ministry of Health of the Russian Federation has approved a clinical trial of an innovative drug for the treatment of breast cancer .
-
54 listed companies are expected to increase their annual performance in 2021. What is the performance of Pharmaceutical Biology?
Time of Update: 2021-12-31
The annual performance forecast disclosed by the company on October 27 shows that the net profit attributable to shareholders of listed companies in 2021 is expected to be 170 million yuan to 187 million yuan.
-
Annual inventory: in 2021, what are the characteristics of "eye-catching" medicinal products?
Time of Update: 2021-12-31
Against the background of the good situation in the domestic pharmaceutical equipment industry, many domestic and foreign pharmaceutical machinery companies have accelerated the introduction of new products and new solutions in order to improve their competitiveness and seize market advantages, which are quite eye-catching.
-
Puli Pharmaceutical's desloratadine dry suspension obtained marketing authorization in the Netherlands
Time of Update: 2021-12-31
Related symptoms of allergic rhinitis and urticaria .
The release of chemical media relieves the symptoms of allergic rhinitis and urticaria .
-
Against prostate cancer!
Time of Update: 2021-12-31
ArticleMedicine GuanlanOn December 6, Impair Pharmaceuticals announced that its PARP inhibitor senaparib (IMP4297) for the treatment of prostate cancer has been approved by the China National Medical Products Administration (NMPA) for a clinical trial application .
-
Guangxi Province Issues a Notice of Establishing and Improving the "Dual Channel" Management Mechanism for National Medical Insurance Negotiation Drugs
Time of Update: 2021-12-31
The "Notice" stated that "dual-channel" medical institutions are encouraged to provide "Internet +" drug circulation services, standardize Internet sales services, and achieve "online ordering store pickup" or "online ordering store delivery" .
-
Hengrui Medicine's new generation of PARP inhibitor fluzoparib (Irei®) is included in the new version of the National Medical Insurance Catalogue in 2021
Time of Update: 2021-12-31
Hengrui Pharmaceuticals independently developed a category 1 innovative drug and China's first original PARP inhibitor fluzoparib successfully entered the new version of the medical insurance catalog .
-
Since the beginning of 2021, more than 200 senior executives in the pharmaceutical industry have resigned!
Time of Update: 2021-12-31
Chu Xiaojun holds a total of 960,000 shares in the company, and she promises to manage the shares held in strict accordance with the relevant regulations on the transfer of directors, supervisors, and senior executives .
-
The traditional Chinese medicine formula granule industry has been "spilled with cold water", and the hard practice of internal strength has become a rigid requirement
Time of Update: 2021-12-30
. After the above-mentioned requirements appear, the industry believes that the current sales of Chinese medicine formula granules in the hospital may be affected .
However, some people in the industry pointed out that these requirements are only regulations for the standardized use of Chinese medicine formula granules.
-
Cinda failed to introduce ISAC drug clinical research and development, Bolt stock price plummeted 56%
Time of Update: 2021-12-30
As a new immunotherapy, the Boltbody ISAC platform consists of three main components: tumor-targeting antibodies, non-degradable linkers, and proprietary immunostimulants (TLR 7/8 agonists) used to activate the patient’s innate immune system .
-
Nalalong original milk powder for the elderly, to protect intestinal health 2022 Jinan Old Expo exhibitors recommended
Time of Update: 2021-12-30
Next year, we will continue to join hands with 300 domestic and foreign institutions and enterprises related to elderly care, health, service, technology and other relevant exhibitions, which will bring more quality elderly care services and products to our country .
-
New domestic hepatitis B drugs will enter medical insurance, and the tens of billions market will be reshaped!
Time of Update: 2021-12-30
Recently, the 2021 national medical insurance catalog released the results of the negotiations, Hansen Pharmaceutical Class 1 hepatitis B drug constant Mu ® (tenofovir tablets Amy) (TMF) also passed Medicare to negotiate for the treatment of chronic hepatitis B in adult patients .
-
Cooperation between pharmaceutical companies and precision diagnosis companies has become a new trend in the industry
Time of Update: 2021-12-30
According to the strategic cooperation memorandum, the two companies will jointly create an end-to-end collaborative innovation service model, covering market access, doctor-patient education, research and development of new biomarkers, and the establishment of a big data platform .
-
The seventh batch of national procurement is ready to come out, the industry: the variety of injections or "the highlight"
Time of Update: 2021-12-30
According to relevant statistics, the terminal sales of this product in China's public medical institutions will be 245 million yuan in 2020.
. For another example, lenvatinib oral dosage form and irinotecan injection have been reviewed by 5 companies, of which irinotecan injection is also a large variety with sales of over 1 billion yuan .
-
The first domestically produced COVID-19 neutralizing antibody combination therapy was approved by the National Food and Drug Administration
Time of Update: 2021-12-30
It is reported that the State Food and Drug Administration, in accordance with the relevant provisions of the Drug Administration Law, in accordance with the special drug approval procedures, conducts emergency review and approval, and approves the above two drugs to be used in combination to treat mild and common types with progress to severe (including hospitalization or Death) Adults and adolescents (12-17 years old, weight ≥40kg) with high-risk factors, patients with novel coronavirus infection (COVID-19) .
-
Fuhong Hanlius' PD-1 inhibitor international multi-center phase III clinical study reaches the primary endpoint of OS
Time of Update: 2021-12-30
The main purpose of this study is to study the effectiveness and safety of slulimumab combined with chemotherapy in ES-SCLC patients who have not received previous treatment .
-
The conditions for applying for a licensed pharmacist have been changed
Time of Update: 2021-12-30
In accordance with the requirements of the "Regulations", those who have obtained the corresponding academic qualifications or degrees in pharmacy and Chinese pharmacy related majors will have a corresponding increase in the number of years of work in pharmacy or Chinese pharmacy by one year .
-
There are new developments in the research and development of domestic children's drugs, and the drug company's innovative drug is approved for RPDD
Time of Update: 2021-12-30
In short, China's children's drug market is still in a situation where there are few special varieties, fewer suitable dosage forms, fewer manufacturers, and high attention from enterprises but low actual research and development enthusiasm .
